These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8587081)

  • 1. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis.
    Ferraz MB; O'Brien B
    J Rheumatol; 1995 May; 22(5):908-14. PubMed ID: 8587081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.
    Saseen JJ; Agashivala N; Allen RR; Ghushchyan V; Yadao AM; Nair KV
    Rheumatology (Oxford); 2012 Nov; 51(11):2004-12. PubMed ID: 22829689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gout and hyperuricaemia--should both be treated?].
    Uhlig T
    Tidsskr Nor Laegeforen; 2003 Oct; 123(20):2878-80. PubMed ID: 14600714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
    Choi HK; Seeger JD; Kuntz KM
    J Rheumatol; 2002 Jun; 29(6):1156-65. PubMed ID: 12064828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis.
    Cattermole GN; Man CY; Cheng CH; Graham CA; Rainer TH
    Eur J Emerg Med; 2009 Oct; 16(5):261-6. PubMed ID: 19521293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should patients with interval gout be treated with urate lowering drugs?
    Fam AG
    J Rheumatol; 1995 Sep; 22(9):1621-3. PubMed ID: 8523333
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy.
    Shoji A; Yamanaka H; Kamatani N
    Arthritis Rheum; 2004 Jun; 51(3):321-5. PubMed ID: 15188314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study.
    Neogi T; Hunter DJ; Chaisson CE; Allensworth-Davies D; Zhang Y
    J Rheumatol; 2006 Jan; 33(1):104-9. PubMed ID: 16267879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Spiegel BM; Chiou CF; Ofman JJ
    Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
    Perez-Ruiz F; Atxotegi J; Hernando I; Calabozo M; Nolla JM
    Arthritis Rheum; 2006 Oct; 55(5):786-90. PubMed ID: 17013833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An economic approach to health care.
    Homik JE; Suarez-Almazor M
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis.
    Stuart RA; Gow PJ; Bellamy N; Campbell J; Grigor R
    N Z Med J; 1991 Mar; 104(908):115-7. PubMed ID: 2011292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.
    Meltzer M; Pizzi LT; Jutkowitz E
    Evid Based Med; 2012 Aug; 17(4):105-8. PubMed ID: 22345034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
    Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
    Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.